Amicus Therapeutics Inc [NASDAQ: FOLD] traded at a high on Thursday, posting a 14.00 gain after which it closed the day’ session at $11.97.
The results of the trading session contributed to over 10189029 shares changing hands. Over the past one week, the price volatility of Amicus Therapeutics Inc stands at 5.32% while the volatility over the past one month is 3.58%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for FOLD stock reached $3.55 billion, with 293.59 million shares outstanding and 289.03 million shares in the current float. Compared to the average trading volume of 2.57M shares, FOLD reached a trading volume of 10189029 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Amicus Therapeutics Inc [FOLD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $17.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.31. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Amicus Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 06, 2024. While these analysts kept the previous recommendation, Wells Fargo raised their target price to Overweight. The new note on the price target was released on May 30, 2024, representing the official price target for Amicus Therapeutics Inc stock. Previously, the target price had yet another raise to $13, while Guggenheim analysts kept a Buy rating on FOLD stock. On December 19, 2023, analysts increased their price target for FOLD shares from 15 to 20.
The Average True Range (ATR) for Amicus Therapeutics Inc is set at 0.42, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 7.79. The Price to Book ratio for the last quarter was 26.77, with the Price to Cash per share for the same quarter was set at 0.88.
How has FOLD stock performed recently?
Amicus Therapeutics Inc [FOLD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.10. With this latest performance, FOLD shares gained by 9.72% in over the last four-week period, additionally plugging by 15.88% over the last 6 months – not to mention a rise of 11.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 68.88, with the RSI for the last a single of trading hit 76.50, and the three-weeks RSI is set at 63.94 for Amicus Therapeutics Inc [FOLD]. The present Moving Average for the last 50 days of trading for this stock 11.15, while it was recorded at 10.74 for the last single week of trading, and 11.23 for the last 200 days.
Amicus Therapeutics Inc [FOLD]: Deeper insight into the fundamentals
Amicus Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.26 and a Current Ratio set at 2.75.
Earnings analysis for Amicus Therapeutics Inc [FOLD]
With the latest financial reports released by the company, Amicus Therapeutics Inc posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FOLD.
Insider trade positions for Amicus Therapeutics Inc [FOLD]
There are presently around $107.58%, or 108.38%% of FOLD stock, in the hands of institutional investors. The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 28.59 million shares, which is approximately 9.4382%. PERCEPTIVE ADVISORS LLC, holding 28.06 million shares of the stock with an approximate value of $$278.33 million in FOLD stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $$271.81 million in FOLD stock with ownership which is approximately 9.0458%.
